Cargando…

Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial

BACKGROUND: Immune checkpoint inhibitors monotherapy has been studied in patients with advanced biliary tract cancer (BTC). The aim of this study was to assess the efficacy and safety of camrelizumab, plus gemcitabine and oxaliplatin (GEMOX) as first-line treatment in advanced BTC and explored the p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Xiaofeng, Wu, Xiaofeng, Wu, Hao, Gu, Yanhong, Shao, Yang, Shao, Qianwen, Zhu, Feipeng, Li, Xiao, Qian, Xiaofeng, Hu, Jun, Zhao, Fengjiao, Mao, Weidong, Sun, Jing, Wang, Jian, Han, Gaohua, Li, Changxian, Xia, Yongxiang, Seesaha, Poshita Kumari, Zhu, Dongqin, Li, Huajun, Zhang, Junling, Wang, Guoqiang, Wang, Xuehao, Li, Xiangcheng, Shu, Yongqian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656907/ https://www.ncbi.nlm.nih.gov/pubmed/33172881 http://dx.doi.org/10.1136/jitc-2020-001240

Ejemplares similares

Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study
por: Chen, Xiaofeng, et al.
Publicado: (2022)

Olaparib combined with immunotherapy for treating a patient with liver cancer carrying BRCA2 germline mutation: A case report
por: Zhao, Fengjiao, et al.
Publicado: (2020)

Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial
por: Xia, Yongxiang, et al.
Publicado: (2022)

Case fatality rate of the adult in-patients with COVID-19 and digestive system tumors: A systematic review and meta-analysis
por: Wang, Guoqun, et al.
Publicado: (2022)

Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients
por: Vici, Patrizia, et al.
Publicado: (2013)

Adjuvant Gemcitabine-Oxaliplatin (GEMOX) after Curative Surgery in High-risk Patients with Cholangiocarcinoma
por: Paule, Bernard, et al.
Publicado: (2010)

Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study
por: Demols, A, et al.
Publicado: (2006)

Immuno-genomic-radiomics to predict response of biliary tract cancer to camrelizumab plus GEMOX in a single-arm phase II trial
por: Liu, Qiu-Ping, et al.
Publicado: (2023)

Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes
por: Chen, Xiaofeng, et al.
Publicado: (2021)

Real-World Evidence on Palliative Gemcitabine and Oxaliplatin (GemOx) Combination Chemotherapy in Advanced Biliary Tract Cancer
por: Lagenfelt, Hanna, et al.
Publicado: (2021)

A Retrospective Case Series Of High-Intensity Focused Ultrasound (HIFU) In Combination With Gemcitabine And Oxaliplatin (Gemox) On Treating Elderly Middle And Advanced Pancreatic Cancer
por: Tao, Shuang-fen, et al.
Publicado: (2019)

P1090: CAMRELIZUMAB (CAM) COMBINED WITH GEMOX CHEMOTHERAPY RESULTS IN HIGH COMPLETE METABOLIC RESPONSE RATES IN RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA (CHL): A PHASE II TRIAL
por: Xie, Y., et al.
Publicado: (2022)

The genomic landscape of cholangiocarcinoma reveals the disruption of post-transcriptional modifiers
por: Zhang, Yaodong, et al.
Publicado: (2022)

Preliminary Efficacy and Safety of Camrelizumab in Combination With XELOX Plus Bevacizumab or Regorafenib in Patients With Metastatic Colorectal Cancer: A Retrospective Study
por: Zhou, Hong, et al.
Publicado: (2021)

The efficacy of oxaliplatin, surufatinib, and camrelizumab on neuroendocrine carcinoma: a case report and literature review
por: Wang, Xianhua, et al.
Publicado: (2022)

PSMC2 Regulates Cell Cycle Progression Through the p21/Cyclin D1 Pathway and Predicts a Poor Prognosis in Human Hepatocellular Carcinoma
por: Liu, Yiwei, et al.
Publicado: (2021)

Case Report: Camrelizumab combined with gemcitabine and oxaliplatin in the treatment of advanced intrahepatic cholangiocarcinoma: a case report and literature review
por: Zhang, Zhongyan, et al.
Publicado: (2023)

Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma
por: Wang, Jing-hua, et al.
Publicado: (2016)

Multicenter, single-arm, phase II study (CAP) of radiotherapy plus liposomal irinotecan followed by camrelizumab and anti-angiogenic treatment in advanced solid tumors
por: Shen, Jie, et al.
Publicado: (2023)

Protocol for a randomized controlled trial of perioperative S-1 plus oxaliplatin combined with apatinib and camrelizumab in patients with resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma
por: Zheng, Yanan, et al.
Publicado: (2020)

Hypoxia‐induced hsa_circ_0000826 is linked to liver metastasis of colorectal cancer
por: Shi, Li, et al.
Publicado: (2020)

Camrelizumab plus gemcitabine and oxaliplatin for the treatment of advanced intrahepatic cholangiocarcinoma: a bi-centric observational retrospective study
por: Zhang, Yu-Qing, et al.
Publicado: (2023)

Rapamycin Regulates iTreg Function through CD39 and Runx1 Pathways
por: Lu, Yunjie, et al.
Publicado: (2014)

Phase I study of camrelizumab in patients with advanced solid tumors
por: Ma, Yuxiang, et al.
Publicado: (2023)

Safety and efficacy of GEMOX plus donafenib and tislelizumab as first‐line therapy for advanced epithelial malignant biliary tract cancer
por: Wang, Longrong, et al.
Publicado: (2023)

Impact of a high dietary fiber cereal meal intervention on body weight, adipose distribution, and cardiovascular risk among individuals with type 2 diabetes
por: Li, Xiaofeng, et al.
Publicado: (2023)

Current Progress and Future Perspectives of Immune Checkpoint Inhibitors in Biliary Tract Cancer
por: Seesaha, Poshita-Kumari, et al.
Publicado: (2021)

A clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapy
por: Qian, Jing, et al.
Publicado: (2016)

Novel nanometer scaffolds regulate the biological behaviors of neural stem cells☆
por: Zhou, Jihui, et al.
Publicado: (2013)

Case Report: Favorable Response and Manageable Toxicity to the Combination of Camrelizumab, Oxaliplatin, and Oral S-1 in a Patient With Advanced Epstein–Barr Virus-Associated Gastric Cancer
por: Lv, Wanrui, et al.
Publicado: (2022)

Three-arm phase II trial comparing camrelizumab plus chemotherapy versus camrelizumab plus chemoradiation versus chemoradiation as preoperative treatment for locally advanced esophageal squamous cell carcinoma (NICE-2 Study)
por: Yang, Yang, et al.
Publicado: (2022)

Evaluation of lncRNA FOXD3-AS1 as a Biomarker for Early-Stage Lung Cancer Diagnosis and Subtype Identification
por: Liu, Xiaofeng, et al.
Publicado: (2022)

Tumor Microenvironment Status Predicts the Efficacy of Postoperative Chemotherapy or Radiochemotherapy in Resected Gastric Cancer
por: Duan, Ran, et al.
Publicado: (2021)

Prognostic factors for operable biliary tract cancer: serum levels of lactate dehydrogenase, a strong association with survival
por: Ma, Ling, et al.
Publicado: (2018)

A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer
por: Zhang, Qingyuan, et al.
Publicado: (2022)

The Safety and Efficacy of Camrelizumab and Its Combination With Apatinib in Various Solid Cancers
por: Wang, Kunlun, et al.
Publicado: (2020)

Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer
por: Zhu, Chengpei, et al.
Publicado: (2023)

Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial
por: Ni, Jun, et al.
Publicado: (2023)

A Single‐Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer
por: Chen, Xiaofeng, et al.
Publicado: (2019)

Dynamics analysis of a delayed virus model with two different transmission methods and treatments
por: Zhang, Tongqian, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1ufdlfnm3nsmgfh675p1ulu50a